Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Open Innovation for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Due Diligence
Comparison
 
Due Diligence
Overview
Top Applications
Online Panel Discussions
Request Consultation
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
Forums
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..4 of 4 - per page
Order by
Two new compounds having HDAC (histone deacetylase) inhibition capability have shown the effect of inducing re-differentiation of human brain and breast cancer cells both in vitro and in vivo. More
The use of vitamin-drug formulations to (a) enable oral absorption of pharmaceutically active ingredients which are not normally absorbed in the GI tract and (b) enhance delivery of drugs to diseases such as cancer and rheumatoid arthritis. More
Novel Cancer Therapy for Epithelial Cancers More
A pharmacogenetic method to identify candidates who are most likely to benefit from treatment with statins to reduce cancer risk, and consequently minimizing any unnecessary cost and side effects in individuals who do not benefit. More
Displaying 1..4 of 4 - per page
Order by

Your selection

Industry sector
Pharmaceutical del
Therapeutic target
Oncology del
Colorectal cancer del

Browse By

Research Partnership for Due Diligence Execution
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us